GEODE-II: Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Low-Dose Ribavirin QD in Patients with Genotype 1a Chronic Hepatitis C Virus Infection without Cirrhosis

被引：0

作者：

Poordad, Fred ^{[1
]}

Sedghi, Shahriar ^{[2
]}

Pockros, Paul J. ^{[12
]}

Ravendhran, Natarajan ^{[3
]}

Reindollar, Robert ^{[4
]}

Lucey, Michael R. ^{[5
]}

Epstein, Michael S. ^{[6
]}

Bank, Leslie ^{[7
]}

Bernstein, David E. ^{[8
]}

Trinh, Roger ^{[9
]}

Krishnan, Preethi ^{[9
]}

Pilot-Matias, Tami ^{[9
]}

Polepally, Akshanth R. ^{[9
]}

Pothacamury, Rajvineeth K. ^{[9
]}

Unnebrink, Kristina ^{[10
]}

Martinez, Marisol ^{[9
]}

Nelson, David R. ^{[11
]}

机构：

[1] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78229 USA

[2] Mercer Univ, Sch Med, Med & Surg, Macon, GA 31207 USA

[3] Digest Dis Associates, Baltimore, MD USA

[4] Piedmont Healthcare Carolinas Ctr Liver Dis, Statesville, NC USA

[5] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Gastroenterol Hepatol, Madison, WI USA

[6] Digest Disorders Associates, Anne Arundel Med Ctr, Annapolis, MD USA

[7] Reg Clin Res Inc, Endwell, NY USA

[8] Hofstra Northwell Sch Med, Manhasset, NY USA

[9] AbbVie Inc, N Chicago, IL USA

[10] AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany

[11] Univ Florida, Dept Med, Gainesvillle, FL USA

[12] Scripps Clin, Div Gastroenterol Hepatol, La Jolla, CA 92037 USA

来源：

HEPATOLOGY | 2016年 / 64卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

872

引用

页码：431A / 432A

页数：2

共 50 条

[1] Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis
Poordad, Fred
Sedghi, Shahriar
Pockros, Paul J.
Ravendhran, Natarajan
Reindollar, Robert
Lucey, Michael R.
Epstein, Michael
Bank, Leslie
Bernstein, David
Trinh, Roger
Krishnan, Preethi
Polepally, Akshanth R.
Unnebrink, Kristina
Martinez, Marisol
Nelson, David R.
JOURNAL OF VIRAL HEPATITIS, 2019, 26 (08) : 1027 - 1030
[2] ZIRCON: pharmacokinetics, safety, and efficacy of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in adolescents with genotype 1 or 4 hepatitis C virus infection
Leung, D. H.
Yao, B.
Viani, R. M.
Gonzalez-Peralta, R. P.
Jonas, M. M.
Lobritto, S. J.
Narkewicz, M. R.
Sokal, E.
Fortuny, C.
Hsu, E.
Wirth, S.
Del Valle-Segarra, A.
Zha, J.
Larsen, L.
Liu, L.
Shuster, D. L.
Cohen, D. E.
Rosenthal, P.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S300 - S301
[3] Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin (RBV) in hepatitis C virus genotype 1-infected patients with compensated cirrhosis and multiple comorbidities
Popa, R. C.
Mihai, C.
Trifan, A.
Stanciu, C.
Gheorghe, L.
Iacob, S.
Arama, V.
Rogoveanu, I.
Diculescu, M.
Goldis, A.
Bataga, S.
Seicean, A.
Sandulescu, L.
Nastase, R.
Molagic, V.
Brisc, C.
Curescu, M.
Prelipcean, C. C.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S732 - S732
[4] Efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir with ribavirin in adults with genotype 1 or genotype 4 chronic hepatitis C virus infection and child-pugh B decompensated cirrhosis
Mantry, P.
Reddy, R.
Cohen, E.
Everson, G.
Ramji, A.
Zeuzem, S.
Gordon, S.
Yoshida, E.
Sherman, M.
Balart, L.
Baumgarten, A.
Lee, S.
Fredrick, L. M.
Abunimeh, M.
Cohen, D. E.
Shulman, N. S.
Wilson, J.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S728 - S729
[5] Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Tablets for Hepatitis C Virus Genotype 1 Infection
Klibanov, Olga M.
Gale, Stormi E.
Santevecchi, Barbara
ANNALS OF PHARMACOTHERAPY, 2015, 49 (05) : 566 - 581
[6] SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR plus DASABUVIR IN CHRONIC HEPATITIS C PATIENTS WITH HCV GENOTYPE 1 INFECTION
Tatara, Tomasz
Dabrowska-Bender, Marta
Duda-Zalewska, Aneta
Staniszewska, Anna
ACTA POLONIAE PHARMACEUTICA, 2019, 76 (04): : 613 - 619
[7] ONYX-II: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Coadministered with Ribavirin in Asian Adults with Genotype 1b Chronic Hepatitis C Virus Infection and Compensated Cirrhosis
Wei, Lai
Wang, Qui-Qiang
Luo, Yan
Chu, Chi-Jen
Paik, Seung Woon
Hou, Jinlin
Cheng, Jun
Xie, Qing
Duan, Zhongping
Kao, Jia-Horng
Fu, Bo
Mobashery, Niloufar
Heo, Jeong
HEPATOLOGY, 2016, 64 : 434A - 434A
[8] Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study
Petta, Salvatore
Marzioni, Marco
Russo, Pierluigi
Aghemo, Alessio
Alberti, Alfredo
Ascione, Antonio
Antinori, Andrea
Bruno, Raffaele
Bruno, Savino
Chirianni, Antonio
Gaeta, Giovanni Battista
Giannini, Edoardo G.
Merli, Manuela
Messina, Vincenzo
Montilla, Simona
Perno, Carlo Federico
Puoti, Massimo
Raimondo, Giovanni
Rendina, Maria
Silberstein, Francesca Ceccherini
Villa, Erica
Zignego, Anna Linda
Pani, Luca
Craxi, Antonio
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (06): : 427 - 434
[9] Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
Liu, Chen-Hua
Liu, Chun-Jen
Su, Tung-Hung
Yang, Hung-Chih
Hong, Chun-Ming
Tseng, Tai-Chung
Chen, Pei-Jer
Chen, Ding-Shinn
Kao, Jia-Horng
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 (03) : 710 - 717
[10] Real-life data on the efficacy and safety of ombitasvir/paritaprevir//ritonavir plus dasabuvir plus ribavirin in the patients with genotype 1 chronic hepatitis C virus infection in Serbia
Babic, Jasmina Simonovic
Bojovic, Ksenija
Fabri, Milotka
Cvejic, Tatjana
Svorcan, Petar
Nozic, Darko
Jovanovic, Maja
Skrbic, Ranko
Stojiljkovic, Milos P.
Mijailovic, Zeljko
VOJNOSANITETSKI PREGLED, 2019, 76 (05) : 531 - 536

← 1 2 3 4 5 →